SCHEMBL21247321

SCHEMBL21247321

COc1ccc(C(=O)Nc2sc3c(c2C(=O)O)C(C)(C)CC3)cc1OC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOD1 Q9Y239 3/20 0.62
▸ MEN1 O00255 6/20 0.58
▸ KMT2A Q03164 6/20 0.58
▸ FLT3 P36888 5/20 0.58
▸ RECQL P46063 1/20 0.58
▸ MAPT P10636 5/20 0.52
▸ TP53 P04637 2/20 0.52
▸ GLO1 Q04760 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ HPGD P15428 3/20 0.47
▸ POLB P06746 3/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ TNF P01375 1/20 0.47
▸ NOD2 Q9HC29 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ HTT P42858 2/20 0.45
▸ CHEK1 O14757 1/20 0.45
▸ PIM1 P11309 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21247188 0.84 NOD1 (0.71) NOD1MEN1KMT2AFLT3RECQL
SCHEMBL21247268 0.82 NOD1 (0.69) NOD1MEN1KMT2AFLT3RECQL
SCHEMBL21253132 0.82 RAB9A (0.58) NOD1MEN1KMT2AFLT3MAPT
SCHEMBL22680797 0.82 NOD1 (0.42) NOD1MEN1KMT2AFLT3RECQL
SCHEMBL21247283 0.81 TNF (0.61) NOD1MEN1KMT2AFLT3MAPT
SCHEMBL21253133 0.80 NOD1 (0.67) NOD1MEN1KMT2AFLT3RECQL
SCHEMBL21261107 0.80 KMT2A (0.55) NOD1MEN1KMT2AFLT3MAPT
SCHEMBL21247261 0.79 GLO1 (0.50) NOD1MEN1KMT2AFLT3MAPT
SCHEMBL21250159 0.79 CNR2 (0.52) NOD1MEN1KMT2AMAPTGLO1
SCHEMBL21261089 0.78 GLO1 (0.49) NOD1MEN1KMT2AFLT3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11492347-B2 Fused thiophene derivatives and their uses ENYO PHARMA (FR) 2022-11-08 — — US disclosed
EP-3749659-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 — — EP disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH NOD1 410/4885MEN1 3538/4885KMT2A 3454/4885
US-11492347-B2 Fused thiophene derivatives and their uses FTH1, SLC40A1, FECH NOD1 410/4885MEN1 3538/4885KMT2A 3454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback